Skip to content

Study · Not a test of the peptide alone · 2026

3 results

Early targets and progressive deterioration in cardiac performance in response to chronically modified cardiac troponin I.

Ravichandran VS, Schatz TM, Lavey E, Salih O, Hur S, Reynolds P, Ruff JJ, Nagidi SH, Van den Bergh F, Soleimanpour SA, Beard DA, Westfall MV

American journal of physiology. Heart and circulatory physiology19 Feb 2026

PMID41711592 (opens in a new tab)DOI10.1152/ajpheart.00517.2025 (opens in a new tab)PepBankPUB-41711592
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

  1. 01AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome

    In transgenic mice with chronic cTnI Ser43/45 phosphomimetic replacement, a second-generation peptide derived from elamipretide improved survival.

    In plain wordsIn mice with heart dysfunction, a new peptide derived from elamipretide helped them live longer.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseSurvival
    Study

    mousen: not reported in source

    Transgenic phosphomimetic cTnI S43/45D mice
    Outcome group
    Mortality · Cardiovascular

    Source sentences

    Summary
    A second-generation peptide derived from elamipretide improved survival and slowed the progression of remodeling and contractile dysfunction.
    1 context sentence
    Summary · context
    To investigate the in vivo impact of this cluster, three lines of transgenic mice were generated with high (HE-), moderate (ME-), and low (LE-) phosphomimetic cTnIS43/45D (SD) replacement of endogenous cTnI within sarcomere thin filament.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  2. 02AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome

    In transgenic mice with chronic cTnI Ser43/45 phosphomimetic replacement, a second-generation peptide derived from elamipretide slowed the progression of remodeling.

    In plain wordsIn mice with heart dysfunction, a new peptide derived from elamipretide slowed harmful changes in heart structure.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseProgression of cardiac remodeling
    Study

    mousen: not reported in source

    Transgenic phosphomimetic cTnI S43/45D mice
    Outcome group
    Heart function · Cardiovascular

    Source sentences

    Summary
    A second-generation peptide derived from elamipretide improved survival and slowed the progression of remodeling and contractile dysfunction.
    1 context sentence
    Summary · context
    To investigate the in vivo impact of this cluster, three lines of transgenic mice were generated with high (HE-), moderate (ME-), and low (LE-) phosphomimetic cTnIS43/45D (SD) replacement of endogenous cTnI within sarcomere thin filament.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

  3. 03AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome

    In transgenic mice with chronic cTnI Ser43/45 phosphomimetic replacement, a second-generation peptide derived from elamipretide slowed the progression of contractile dysfunction.

    In plain wordsIn mice with heart dysfunction, a new peptide derived from elamipretide slowed the loss of heart pumping strength.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseProgression of contractile dysfunction
    Study

    mousen: not reported in source

    Transgenic phosphomimetic cTnI S43/45D mice
    Outcome group
    Heart function · Cardiovascular

    Source sentences

    Summary
    A second-generation peptide derived from elamipretide improved survival and slowed the progression of remodeling and contractile dysfunction.
    1 context sentence
    Summary · context
    To investigate the in vivo impact of this cluster, three lines of transgenic mice were generated with high (HE-), moderate (ME-), and low (LE-) phosphomimetic cTnIS43/45D (SD) replacement of endogenous cTnI within sarcomere thin filament.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.